Nordea Investment Management AB grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.4% in the ...

Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...

Highline Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) in the fourth quarter, according to the company in its most recent filing with the ...

Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to ...

“With CRSP as the leading equities pricing data used by academic researchers, and OptionMetrics considered by many to be the ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $41.92, demonstrating a -1.2% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a ...

CRISPR Therapeutics (CRSP) proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company’s annual general meeting to be ...

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $85 from $98 and keeps a Buy rating on the shares.

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...